Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone liposome + cytarabine + etoposide for newly diagnosed de novo AML
ChiCTR2400080919Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Feb 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone, cytarabine and etoposide in acute myeloid leukemia (AML), sponsored by Union Hospital. Primary endpoint: Composite complete remission rate. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
mitoxantronecytarabineetoposide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400080919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080919.